Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT01311414 Withdrawn - Cerebral Ischemia Clinical Trials

Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation

NIRSMED
Start date: n/a
Phase: N/A
Study type: Interventional

During clamping of one internal carotid artery for endarterectomy, blood flow through this vessel has to be compensated by collateral arteries including the contralateral internal artery and vertebral arteries. In 7 % of all patients undergoing carotid endarterectomy this collateral flow is not sufficient to maintain adequate cerebral perfusion during clamping and ischemic brain damage is likely to emerge. To maximize cerebral blood flow during clamping, increase of blood pressure is a common procedure and routine at our institution. Increasing blood pressure can be enabled by tapering a mixture of Cafedrine und Theodrenalin (Akrinor®) until the designated blood pressure is reached. After declamping, the blood pressure has to be reduced to normal values to avoid postoperative hyperperfusion syndrome. This is enabled by tapering urapidil until normal blood pressure is achieved. It has been shown that cerebral oxygenation measured by near infrared spectroscopy is reduced by intravenous application of norepinephrine. Otherwise, intravenous nitroglycerine increases cerebral oxygenation during cardiopulmonary bypass. Hence, cafedrine/theodrenalin and urapidil may also have an effect on cerebral perfusion. In this prospective randomized study the effect of cafedrine/theodrenalin and urapidil on cerebral oxygenation measured by near infrared spectroscopy is investigated.

NCT ID: NCT01297413 Completed - Ischemic Stroke Clinical Trials

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

Start date: February 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.

NCT ID: NCT01287936 Completed - Clinical trials for Chronic Ischemic Stroke

A Study of Modified Stem Cells in Stable Ischemic Stroke

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.

NCT ID: NCT01273467 Completed - Stroke Clinical Trials

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke. The study is not designed to establish efficacy, although preliminary explorations will be conducted.

NCT ID: NCT01273337 Unknown status - Stroke Clinical Trials

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Start date: March 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the middle cerebral artery (MCA). ALD-401 is made from the stroke patient's bone marrow and infused 13-19 days after the stroke.

NCT ID: NCT01264549 Completed - Ischemic Stroke Clinical Trials

Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)

STRAWINSKI
Start date: December 2010
Phase: N/A
Study type: Interventional

Development of stroke associated pneumonia (SAP) has a detrimental effect on stroke outcome. Biomarker-guided antibiotic treatment of patients at high risk for pneumonia may help to improve stroke outcome. Therefore, the investigators will evaluate whether intensified infection monitoring via Procalcitonin guiding an early standardized antibiotic treatment improves functional outcome after stroke compared with standard therapy based on current guidelines.

NCT ID: NCT01187420 Completed - Clinical trials for Subarachnoid Hemorrhage

Bilateral Bispectral Index (BIS) Study

BIS
Start date: June 2009
Phase: N/A
Study type: Observational

The purpose of this study is to assess real time changes in raw and processed EEG in relation to the clinical and radiological evidence of cerebral vasospasm.

NCT ID: NCT01174693 Completed - Cerebral Infarction Clinical Trials

Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

MAESTRO
Start date: March 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the preventive effect of stroke between triflusal and clopidogrel in ischemic stroke patient based on the cytochrome P450 2C19 (CYP2C19) polymorphism.

NCT ID: NCT01104467 Completed - Clinical trials for Acute Ischemic Stroke

Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke

DIAS-J
Start date: August 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate whether desmoteplase is safe and tolerated when given to Japanese patients with acute ischemic stroke

NCT ID: NCT01101711 Completed - Quality of Life Clinical Trials

Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage

Start date: November 2006
Phase: N/A
Study type: Observational

Investigation of the incidence of endocrine dysfunction following subarachnoid hemorrhage (SAH), and to see if this has a relation to CNS lesions as evaluated by MRI and to common symptoms after SAH such as general exhaustion, lack of initiative, increased sleep demand and reduced quality of life.